Drug Search Results
More Filters [+]

Arimoclomol

Alternative Names: arimoclomol
Latest Update: 2024-10-22
Latest Update Note: News Article

Product Description

Arimoclomol, taken at a dose of 200 mg three times daily will improve survival as defined by time to death, tracheostomy or permanent assisted ventilation. In addition, it will be safe and well tolerated in subjects with SOD1 positive familial ALS. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00706147)

Mechanisms of Action: HSP70 Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Amyotrophic Lateral Sclerosis *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Orphazyme
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Arimoclomol

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Investigate study drug Arimoclomol with patients diagnosed with Niemann Pick disease type C.

P3

Active, not recruiting

Unknown

2021-04-19

Recent News Events